Results 161 to 170 of about 1,795,367 (304)

Synthetic lethality in TP53-mutant acute myeloid leukemia. [PDF]

Blood Adv
Patel SA.
europepmc   +1 more source

Acute myeloid leukemia

HemaSphere, 2019
openaire   +3 more sources

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Mutational profiling in acute myeloid leukemia. [PDF]

Haematologica
DiNardo CD.
europepmc   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source

Novel treatment strategies in acute myeloid leukemia. [PDF]

Blood Res
Simkhada S, Joshi U, Dhakal P.
europepmc   +1 more source

Risk of Bias Associated with Varying Sampling Strategies for External Comparator Cohorts for Single‐Arm Trials: Insights from Aggressive Lymphoma

Clinical Pharmacology &Therapeutics, EarlyView.
Marketing authorizations for oncology drugs are often based on single‐arm trials (SATs), and real‐world data‐based external comparator cohorts (ECCs) are increasingly explored to contextualize results. In retrospective studies, comparators may be identified by time of diagnosis but included based on time of relapse; such sampling strategies can ...
Mikkel Runason Simonsen, Shiva Leisner, Ahmed Ludvigsen Al‐Mashhadi, Laurids Østergaard Poulsen, Matthew Maurer, Lasse Hjort Jakobsen, Tarec Christoffer El‐Galaly   +6 more
wiley   +1 more source

Artificial Intelligence for Personalized Management of Acute Myeloid Leukemia. [PDF]

J Pers Med
Niscola P, Gianfelici V, Laureana R, Giovannini M, Mazzone C, Efficace F, Principe MID.   +6 more
europepmc   +1 more source

A Robust Computational Workflow Utilizing Generalized Least Squares (GLS) and Generalized Estimating Equations (GEE‐GLM) for Longitudinal Flow Cytometry Maturation Data Analysis

Cytometry Part A, EarlyView.
ABSTRACT Routinely used statistical hypothesis tests are often inadequate for longitudinal flow cytometry data, necessitating more sophisticated modeling approaches. Analyzing dynamic biomarker expression across hematopoietic maturation presents several analytical challenges, notably nonlinearity, serial correlation between subsequent stages, and ...
Sixuan Joanna Wang, Ruben Deneer, Tom Schoenmakers, Stefan G. C. Mestrum, Yvonne M. C. Henskens, Otto Bekers, Anton H. N. Hopman, Frans C. S. Ramaekers, Mathie P. G. Leers   +8 more
wiley   +1 more source

Whole genome sequencing in acute myeloid leukemia. [PDF]

Haematologica
Haferlach T.
europepmc   +1 more source